球囊血管成形术与药物治疗对颅内动脉狭窄的疗效比较:BASIS随机临床试验
BASIS试验在中国31个中心纳入症状性颅内动脉粥样硬化性狭窄(sICAS)患者,随机接受次最大球囊血管成形术联合强化药物治疗(249例)或单纯强化药物治疗(252例)。球囊组主要复合终点发生率为4.4%,低于药物组的13.5%(HR 0.32,95%CI 0.16-0.63,P<.001)。作者认为球囊血管成形术联合强化药物治疗可能有效,但临床实践中应考虑球囊术后30天内卒中或死亡风险。
要点
- 球囊组主要复合终点4.4% vs 药物组13.5%,HR 0.32(95%CI 0.16-0.63),P<.001。
- 球囊组30天内任何卒中或全因死亡3.2%,药物组1.6%。
- 球囊组症状性颅内出血1.2%,药物组0.4%;球囊组手术并发症17.4%,动脉夹层14.5%。
核心结论
- 在sICAS患者中,与单纯强化药物治疗相比,球囊血管成形术联合强化药物治疗统计学显著降低了30天内任何卒中或死亡、或30天后至12个月责任动脉供血区缺血性卒中或责任动脉血运重建的复合终点风险(HR 0.32,95%CI 0.16-0.63,P<.001)。
- 作者认为球囊血管成形术联合强化药物治疗可能是sICAS的有效治疗,但临床实践中应考虑球囊血管成形术后30天内卒中或死亡的风险。
研究设计与样本
- 随机、开放标签、盲法终点临床试验,在中国31个中心开展。
- 2018年11月8日至2022年4月2日招募,最终随访2023年4月3日。
- 纳入35至80岁、入组前90天内短暂性脑缺血发作或14至90天内缺血性卒中、归因于主要颅内动脉70%至99%动脉粥样硬化性狭窄、且接受至少1种抗血栓药物和/或标准危险因素管理的患者。
- 随机接受次最大球囊血管成形术联合强化药物治疗(n=249)或单纯强化药物治疗(n=252);强化药物治疗包括前90天双联抗血小板治疗和危险因素控制。
主要发现
- 512例随机患者中501例确认合格并完成试验(平均年龄58.0岁;女性158例[31.5%])。
- 主要复合终点发生率球囊组4.4% vs 药物组13.5%(HR 0.32,95%CI 0.16-0.63,P<.001)。
- 30天内任何卒中或全因死亡率球囊组3.2% vs 药物组1.6%。
- 入组30天后至1年,责任动脉供血区任何缺血性卒中发生率球囊组0.4% vs 药物组7.5%;责任动脉血运重建发生率球囊组1.2% vs 药物组8.3%。
- 症状性颅内出血发生率球囊组1.2% vs 药物组0.4%;球囊组手术并发症17.4%,动脉夹层14.5%。
临床怎么用
- 作者认为球囊血管成形术联合强化药物治疗可能是sICAS的有效治疗,但临床实践中应考虑球囊血管成形术后30天内卒中或死亡的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous randomized clinical trials did not demonstrate the superiority of endovascular stenting over aggressive medical management for patients with symptomatic intracranial atherosclerotic stenosis (sICAS). However, balloon angioplasty has not been investigated in a randomized clinical trial. OBJECTIVE: To determine whether balloon angioplasty plus aggressive medical management is superior to aggressive medical management alone for patients with sICAS. DESIGN, SETTING, AND PARTICIPANTS: A randomized, open-label, blinded end point clinical trial at 31 centers across China. Eligible patients aged 35 to 80 years with sICAS defined as recent transient ischemic attack (<90 days) or ischemic stroke (14-90 days) before enrollment attributed to a 70% to 99% atherosclerotic stenosis of a major intracranial artery receiving treatment with at least 1 antithrombotic drug and/or standard risk factor management were recruited between November 8, 2018, and April 2, 2022 (final follow-up: April 3, 2023). INTERVENTIONS: Submaximal balloon angioplasty plus aggressive medical management (n = 249) or aggressive medical management alone (n = 252). Aggressive medical management included dual antiplatelet therapy for the first 90 days and risk factor control. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of any stroke or death within 30 days after enrollment or after balloon angioplasty of the qualifying lesion or any ischemic stroke in the qualifying artery territory or revascularization of the qualifying artery after 30 days through 12 months after enrollment. RESULTS: Among 512 randomized patients, 501 were confirmed eligible (mean age, 58.0 years; 158 [31.5%] women) and completed the trial. The incidence of the primary outcome was lower in the balloon angioplasty group than the medical management group (4.4% vs 13.5%; hazard ratio, 0.32 [95% CI, 0.16-0.63]; P < .001). The respective rates of any stroke or all-cause death within 30 days were 3.2% and 1.6%. Beyond 30 days through 1 year after enrollment, the rates of any ischemic stroke in the qualifying artery territory were 0.4% and 7.5%, respectively, and revascularization of the qualifying artery occurred in 1.2% and 8.3%, respectively. The rate of symptomatic intracranial hemorrhage in the balloon angioplasty and medical management groups was 1.2% and 0.4%, respectively. In the balloon angioplasty group, procedural complications occurred in 17.4% of patients and arterial dissection occurred in 14.5% of patients. CONCLUSIONS AND RELEVANCE: In patients with sICAS, balloon angioplasty plus aggressive medical management, compared with aggressive medical management alone, statistically significantly lowered the risk of a composite outcome of any stroke or death within 30 days or an ischemic stroke or revascularization of the qualifying artery after 30 days through 12 months. The findings suggest that balloon angioplasty plus aggressive medical management may be an effective treatment for sICAS, although the risk of stroke or death within 30 days of balloon angioplasty should be considered in clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03703635.
引用
- Sun X, Deng Y, Zhang Y, et al. Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis: The BASIS Randomized Clinical Trial. JAMA. 2024. PMID: 39235816. doi:10.1001/jama.2024.12829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。